Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Novartis
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01301807
First received: February 21, 2011
Last updated: September 7, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)